OFIX · Orthofix Medical
AI read · Bad for OFIX
The AI's read
Growth in Limb Reconstruction and Therapeutic Solutions, along with steadier U.S. Biologics sales, shows that some parts are improving. But soft spine demand and supplier delays limited inventory and surgical tool sets. The company also cited those problems in its full-year sales and adjusted profit ranges, so they weigh more than the gains elsewhere.